STOCK TITAN

Nordson Corporation Completes Acquisition of Atrion Corporation

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)

Nordson (Nasdaq: NDSN) has completed the acquisition of Atrion , a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions. This strategic move expands Nordson's medical portfolio into new markets and therapies, supported by long-term secular growth trends. The acquisition, initially announced on May 28, 2024, aligns with Nordson's innovative precision technology focus and scalable growth framework.

Nordson will provide further details about the acquisition during its third quarter fiscal year 2024 webcast scheduled for Thursday, August 22, 2024, at 8:30 AM ET. The company, founded in 1954 and headquartered in Westlake, Ohio, leverages a direct sales model and applications expertise to serve global customers across consumer non-durable, medical, electronics, and industrial end markets.

Nordson (Nasdaq: NDSN) ha completato l'acquisizione di Atrion, un leader nella consegna di fluidi infusionali medici proprietari e soluzioni cardiovascolari di nicchia. Questa mossa strategica amplia il portafoglio medico di Nordson in nuovi mercati e terapie, supportata da tendenze di crescita secolare a lungo termine. L'acquisizione, annunciata inizialmente il 28 maggio 2024, è in linea con il focus di Nordson sulle tecnologie di precisione innovative e un framework di crescita scalabile.

Nordson fornirà ulteriori dettagli sull'acquisizione durante il suo webcast del terzo trimestre dell'anno fiscale 2024 programmato per giovedì 22 agosto 2024, alle 8:30 AM ET. L'azienda, fondata nel 1954 e con sede a Westlake, Ohio, sfrutta un modello di vendita diretto e competenze applicative per servire clienti globali nei mercati finali dei consumabili non durevoli, medico, elettronico e industriale.

Nordson (Nasdaq: NDSN) ha completado la adquisición de Atrion, líder en la entrega de fluidos infusionales médicos propios y soluciones cardiovasculares de nicho. Este movimiento estratégico amplía el portafolio médico de Nordson en nuevos mercados y terapias, respaldado por tendencias de crecimiento secular a largo plazo. La adquisición, anunciada inicialmente el 28 de mayo de 2024, se alinea con el enfoque de Nordson en tecnología de precisión innovadora y un marco de crecimiento escalable.

Nordson proporcionará más detalles sobre la adquisición durante su webcast del tercer trimestre del año fiscal 2024, programado para el jueves 22 de agosto de 2024, a las 8:30 AM ET. La empresa, fundada en 1954 y con sede en Westlake, Ohio, utiliza un modelo de ventas directas y experiencia en aplicaciones para atender a clientes globales en los mercados finales de consumidores no duraderos, médico, electrónico e industrial.

Nordson (Nasdaq: NDSN)은 Atrion을 인수했다고 발표했습니다. Atrion은 독점 의약품 주입 유체 전달 및 틈새 심혈관 솔루션의 선두주자입니다. 이 전략적 움직임은 Nordson의 의료 포트폴리오를 새로운 시장과 치료법으로 확장하며, 장기적인 세속적 성장 추세에 의해 뒷받침됩니다. 인수는 2024년 5월 28일에 처음 발표되었으며, Nordson의 혁신적인 정밀 기술 초점과 확장 가능한 성장 프레임워크와 일치합니다.

Nordson은 2024 회계연도 3분기 웹캐스트에서 인수에 대한 추가 세부 정보를 제공할 예정이며, 이는 2024년 8월 22일 목요일 오전 8시 30분 ET에 예정되어 있습니다. 1954년에 설립되어 오하이오주 웨스트레이크에 본사를 둔 이 회사는 직접 판매 모델과 응용 전문성을 활용하여 비소비재, 의료, 전자 및 산업 최종 시장에서 전 세계 고객에게 서비스를 제공합니다.

Nordson (Nasdaq: NDSN) a finalisé l'acquisition de Atrion, un leader dans la livraison de fluides médicaux d'infusion propriétaires et des solutions cardiovasculaires de niche. Ce mouvement stratégique élargit le portefeuille médical de Nordson vers de nouveaux marchés et thérapies, soutenu par des tendances de croissance séculaires à long terme. L'acquisition, initialement annoncée le 28 mai 2024, est en accord avec l'accent mis par Nordson sur la technologie de précision innovante et un cadre de croissance évolutif.

Nordson fournira d'autres détails sur l'acquisition lors de son webinaire du troisième trimestre de l'exercice fiscal 2024, prévu pour le jeudi 22 août 2024, à 8h30 ET. La société, fondée en 1954 et dont le siège est à Westlake, Ohio, exploite un modèle de vente directe et une expertise applicative pour servir des clients du monde entier dans les marchés finaux des biens de consommation non durables, de la santé, de l'électronique et de l'industrie.

Nordson (Nasdaq: NDSN) hat die Übernahme von Atrion abgeschlossen, einem führenden Anbieter im Bereich der proprietären medizinischen Infusionsflüssigkeitsabgabe und Nischenlösungen im kardiovaskulären Bereich. Dieser strategische Schritt erweitert das medizinische Portfolio von Nordson in neue Märkte und Therapien, unterstützt durch langfristige Wachstumstrends. Die Übernahme, die ursprünglich am 28. Mai 2024 angekündigt wurde, steht im Einklang mit Nordsons Fokus auf innovative Präzisionstechnologie und ein skalierbares Wachstumsmodell.

Nordson wird während seiner Webcast zum dritten Quartal des Geschäftsjahres 2024, der für Donnerstag, den 22. August 2024, um 8:30 Uhr ET geplant ist, weitere Details zur Übernahme bekannt geben. Das Unternehmen, das 1954 gegründet wurde und seinen Sitz in Westlake, Ohio hat, nutzt ein Direktvertriebsmodell und Anwendungsexpertise, um globale Kunden in den Endmärkten für Konsumgüter, Medizin, Elektronik und Industrie zu bedienen.

Positive
  • Expansion into new medical markets and therapies
  • Alignment with long-term secular growth trends
  • Strengthening of Nordson's medical portfolio
  • Potential for increased market share in medical technology sector
Negative
  • None.

Insights

Nordson's acquisition of Atrion marks a strategic expansion into new medical markets, potentially boosting its revenue streams and market share. This move aligns with the growing trend of consolidation in the medical device industry, as companies seek to diversify their portfolios and tap into high-growth segments.

The deal's financial impact remains undisclosed, but investors should watch for potential synergies and margin improvements in Nordson's upcoming earnings reports. The acquisition's success will hinge on Nordson's ability to integrate Atrion's operations efficiently and leverage its proprietary technologies to drive innovation and market penetration.

While this expansion could enhance Nordson's long-term growth prospects, investors should also consider the integration risks and potential short-term impacts on the company's balance sheet. The medical device market's regulatory environment and reimbursement landscape will be important factors to monitor as Nordson navigates this new territory.

Nordson's acquisition of Atrion is a strategic move into the high-growth medical infusion and cardiovascular markets. Atrion's expertise in proprietary fluid delivery systems could complement Nordson's existing medical portfolio, potentially leading to innovative product developments.

The medical infusion market is experiencing steady growth due to the rising prevalence of chronic diseases and an aging population. Atrion's niche cardiovascular solutions also position Nordson to capitalize on the increasing demand for minimally invasive procedures.

Investors should note that success in these markets requires continuous R&D investment and navigating complex regulatory pathways. Nordson's ability to leverage Atrion's intellectual property and integrate it with their own technologies will be important for long-term value creation in this competitive landscape.

WESTLAKE, Ohio--(BUSINESS WIRE)-- Nordson Corporation (Nasdaq: NDSN) (the “Company” or “Nordson”) has completed the acquisition of Atrion Corporation (“Atrion”), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions. The completion of the transaction follows the Company’s May 28, 2024 announcement that it had entered into an agreement to acquire the business. This acquisition will expand Nordson’s medical portfolio into new markets and therapies, supported by long-term secular growth trends.

The Company will provide comments about the acquisition in its previously announced third quarter fiscal year 2024 webcast, which is scheduled for:

Date: Thursday, August 22, 2024
Time: 8:30 AM ET
Link to listen: https://events.q4inc.com/attendee/410848164

Investors who are interested in listening to the webcast, but are not able to participate during the scheduled time, can access the replay by visiting Nordson’s investor website.

Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework through an entrepreneurial, division-led organization to deliver top tier growth with leading margins and returns. The Company’s direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has operations and support offices in over 35 countries. Visit Nordson on the web at www.nordson.com, www.twitter.com/Nordson_Corp or www.facebook.com/nordson.

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “could,” “expects,” “anticipates,” “believes,” “projects,” “forecasts,” “outlook,” “guidance,” “continue,” “target,” or the negative of these terms or comparable terminology. These statements reflect management’s current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions, including the Company’s ability to successfully integrate acquisitions; the Company’s ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, including the conflict between Russia and Ukraine, acts of terror, natural disasters and pandemics, including the recent coronavirus (COVID-19) pandemic and the other factors discussed in Item 1A (Risk Factors) in the Company’s most recently filed Annual Report on Form 10-K and in its Forms 10-Q filed with the Securities and Exchange Commission, which should be reviewed carefully. The Company undertakes no obligation to update or revise any forward-looking statement in this press release.

Lara Mahoney

Vice President,

Corporate Communications & Investor Relations

440.204.9985

Lara.Mahoney@nordson.com

Source: Nordson Corporation

FAQ

When did Nordson complete the acquisition of Atrion ?

Nordson completed the acquisition of Atrion as announced in the press release. The exact completion date is not specified, but it occurred after the initial announcement on May 28, 2024.

What are the main products or solutions offered by Atrion ?

Atrion is a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions.

How will the Atrion acquisition impact Nordson's business (NDSN)?

The acquisition will expand Nordson's medical portfolio into new markets and therapies, supported by long-term secular growth trends. This is expected to strengthen Nordson's position in the medical technology sector.

When will Nordson (NDSN) provide more details about the Atrion acquisition?

Nordson will provide comments about the acquisition during its third quarter fiscal year 2024 webcast, scheduled for Thursday, August 22, 2024, at 8:30 AM ET.

Nordson Corp

NASDAQ:NDSN

NDSN Rankings

NDSN Latest News

NDSN Stock Data

14.40B
57.18M
10.13%
76.83%
2.12%
Specialty Industrial Machinery
General Industrial Machinery & Equipment, Nec
Link
United States of America
WESTLAKE